NO992106L - Terapeutisk anvendelse av vekstfaktor og leveringsanordning, spesielt for behandling av intimal hyperplasi - Google Patents

Terapeutisk anvendelse av vekstfaktor og leveringsanordning, spesielt for behandling av intimal hyperplasi

Info

Publication number
NO992106L
NO992106L NO992106A NO992106A NO992106L NO 992106 L NO992106 L NO 992106L NO 992106 A NO992106 A NO 992106A NO 992106 A NO992106 A NO 992106A NO 992106 L NO992106 L NO 992106L
Authority
NO
Norway
Prior art keywords
treatment
intimal hyperplasia
growth factor
delivery device
therapeutic use
Prior art date
Application number
NO992106A
Other languages
English (en)
Other versions
NO992106D0 (no
NO326303B1 (no
Inventor
John Francis Martin
Seppo Ylo-Herrttuala
Stephen George Edward Barker
Original Assignee
Eurogene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622852.3A external-priority patent/GB9622852D0/en
Priority claimed from GBGB9709494.0A external-priority patent/GB9709494D0/en
Priority claimed from GBGB9717791.9A external-priority patent/GB9717791D0/en
Application filed by Eurogene Ltd filed Critical Eurogene Ltd
Publication of NO992106D0 publication Critical patent/NO992106D0/no
Publication of NO992106L publication Critical patent/NO992106L/no
Publication of NO326303B1 publication Critical patent/NO326303B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • External Artificial Organs (AREA)
NO19992106A 1996-11-01 1999-04-30 Anvendelse av VEGF protein for behandling av intimal hyperplasi NO326303B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9622852.3A GB9622852D0 (en) 1996-11-01 1996-11-01 Treatment of intimal hyperplasma
GBGB9709494.0A GB9709494D0 (en) 1997-05-09 1997-05-09 Delivery device and method
GBGB9717791.9A GB9717791D0 (en) 1997-08-21 1997-08-21 Treatment of intimal hyperplasia
PCT/GB1997/003015 WO1998020027A2 (en) 1996-11-01 1997-11-03 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Publications (3)

Publication Number Publication Date
NO992106D0 NO992106D0 (no) 1999-04-30
NO992106L true NO992106L (no) 1999-06-30
NO326303B1 NO326303B1 (no) 2008-11-03

Family

ID=27268562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992106A NO326303B1 (no) 1996-11-01 1999-04-30 Anvendelse av VEGF protein for behandling av intimal hyperplasi

Country Status (14)

Country Link
US (1) US7320679B2 (no)
EP (2) EP1488761A1 (no)
JP (3) JP2001503755A (no)
KR (1) KR100695590B1 (no)
AT (1) ATE287271T1 (no)
AU (1) AU729420B2 (no)
CA (1) CA2270286C (no)
DE (1) DE69732304T2 (no)
ES (1) ES2235227T3 (no)
HU (1) HU223957B1 (no)
NO (1) NO326303B1 (no)
PL (1) PL189744B1 (no)
PT (1) PT941116E (no)
WO (1) WO1998020027A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
FR2792531B1 (fr) * 1999-04-26 2003-01-31 Aventis Pharma Sa Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
JP2002543097A (ja) * 1999-04-26 2002-12-17 アバンテイス・フアルマ・エス・アー 肺動脈高血圧を治療するための血管新生促進因子をコードする核酸を含む組換え欠陥アデノウイルスの使用
IL148826A0 (en) * 1999-09-23 2002-09-12 An Go Gen Inc Cell-based gene therapy for the pulmonary system
WO2001032695A2 (en) * 1999-11-02 2001-05-10 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
SE0000285D0 (sv) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
EP2572674A3 (en) * 2001-07-06 2013-08-07 Syntach AG Implantable blood pressure regulator device
SE0102578L (sv) * 2001-07-20 2003-01-21 Oeyvind Reitan Förändring av en stents egenskaper för att förhindra restenos
AU2003273391A1 (en) * 2003-06-18 2005-01-04 Georg-August-Universitat Gottingen Use of a vegf receptor gene or gene product
GB0515140D0 (en) * 2005-07-22 2005-08-31 Ark Therapeutics Ltd Therapeutic device
WO2007022287A2 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified vegf and pdgf with improved angiogenic properties
ATE476986T1 (de) * 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
US8721711B2 (en) 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
US8808255B2 (en) 2007-12-14 2014-08-19 Oregon Health & Science University Drug delivery cuff
DE102008002396A1 (de) 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
WO2013135266A1 (en) 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
IN2015DN00934A (no) 2012-08-01 2015-06-12 United Therapeutics Corp
AU2014205557B2 (en) 2013-01-09 2017-08-10 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US11571444B2 (en) 2016-10-24 2023-02-07 United Therapeutics Corporation Enhancement of MSC immunomodulatory properties by treprostinil
WO2020204601A1 (ko) * 2019-04-05 2020-10-08 한국세라믹기술원 Csq-태그를 이용한 단백질의 발현 및 정제 방법
IT201900012537A1 (it) * 2019-07-22 2021-01-22 Milano Politecnico Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
US5201728A (en) * 1991-05-03 1993-04-13 Giampapa Vincent C Subcutaneous implantable multiple-agent delivery system
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
EP1027834A1 (en) * 1993-06-11 2000-08-16 The Board of Trustees of The Leland Stanford Junior University Food composition comprising L-arginine
US5653744A (en) * 1995-04-27 1997-08-05 Khouri Biomedical Research, Inc. Device and method for vascular anastomosis
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor

Also Published As

Publication number Publication date
DE69732304T2 (de) 2005-06-02
HUP9902867A2 (hu) 1999-12-28
KR100695590B1 (ko) 2007-03-14
US7320679B2 (en) 2008-01-22
HUP9902867A3 (en) 2001-12-28
WO1998020027A2 (en) 1998-05-14
KR20000052999A (ko) 2000-08-25
NO992106D0 (no) 1999-04-30
DE69732304D1 (de) 2005-02-24
NO326303B1 (no) 2008-11-03
JP2012031196A (ja) 2012-02-16
PL333272A1 (en) 1999-11-22
AU4790697A (en) 1998-05-29
CA2270286A1 (en) 1998-05-14
AU729420B2 (en) 2001-02-01
EP0941116A2 (en) 1999-09-15
US20030225020A1 (en) 2003-12-04
JP4783797B2 (ja) 2011-09-28
ES2235227T3 (es) 2005-07-01
JP2008155036A (ja) 2008-07-10
WO1998020027A3 (en) 1998-10-08
ATE287271T1 (de) 2005-02-15
CA2270286C (en) 2009-03-03
HU223957B1 (hu) 2005-03-29
EP0941116B1 (en) 2005-01-19
JP2001503755A (ja) 2001-03-21
EP1488761A1 (en) 2004-12-22
PL189744B1 (pl) 2005-09-30
HK1108845A1 (zh) 2008-05-23
PT941116E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
NO992106D0 (no) Terapeutisk anvendelse av vekstfaktor og leveringsanordning, spesielt for behandling av intimal hyperplasi
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
WO1996004955A3 (en) Polymer matrix drug delivery apparatus and method
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
UA32429C2 (uk) Засіб для лікування нетримання сечі
GB9106678D0 (en) Wound healing
TW250435B (no)
HU9501841D0 (en) Therapeutic combination containing interferon
GB9321061D0 (en) Analgestic agent and its use
MY164077A (en) Compositions and uses of et743 for treating cancer
AU4634089A (en) Needle and therapeutic device for stimulating specific points of the body
EP0324802A4 (en) Method for the treatment of body tissues and the administration of drugs thereto
GR3022030T3 (en) Composition for treating mastitis and metritis
UA42685C2 (uk) Спосіб судинорозширювальної терапії
WO2001005445A3 (en) A carbon dioxide generating device for medical treatment
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
EP0293925A3 (en) Compound active in cardiovasular therapy
JPH065809Y2 (ja) ペニス用磁気バンド
UA37509A (uk) Спосіб лікування фето-плацентарної недостатності
PT76551B (en) Hydantoin therapeutic agents
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
IL91479A0 (en) Device for use in medical treatment of wounds
ZA93199B (en) An apparatus for use in therapeutic and/or medical treatment.
RU94007838A (ru) Способ лечения геморрагической лихорадки с почечным синдромом

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees